
MediWound (MDWD) Stock Forecast & Price Target
MediWound (MDWD) Analyst Ratings
Bulls say
MediWound Ltd reported total revenues of $4.0 million for Q1 2024, slightly below the consensus estimate of $5.08 million. The company experienced a net loss of $0.7 per share, which was marginally worse than the consensus estimated loss of $0.65 per share. Despite these results, MediWound's focus on developing innovative biopharmaceutical products and its existing FDA-approved product, NexoBrid, position it favorably in the market for addressing significant medical needs, supporting a positive long-term outlook for the company's stock.
Bears say
MediWound Ltd has postponed the anticipated launch of its product EscharEx in the U.S. by one year, now expected in the third quarter of 2028, which may hamper revenue growth prospects. The company currently reports no income from discontinued operations, indicating a lack of cash flow generation during this uncertain period. These factors collectively contribute to a negative outlook for the stock, highlighting delays in product development and potential future revenue challenges.
This aggregate rating is based on analysts' research of MediWound and is not a guaranteed prediction by Public.com or investment advice.
MediWound (MDWD) Analyst Forecast & Price Prediction
Start investing in MediWound (MDWD)
Order type
Buy in
Order amount
Est. shares
0 shares